Dr. O’Shaughnessy on Pembrolizumab in Triple-Negative Breast Cancer
Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.
Optimizing Treatment Strategies in Breast Cancer: Q&A
Fielding questions from their live audience, Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, discuss optimal selection of therapy for patients with breast cancer.
Clinical Trials in HER2+ mBC: DESTINY-Breast03 and HER2CLIMB
Highlights of the results from the DESTINY-Breast03 and HER2CLIMB trials, evaluating T-DXd and tucatinib, respectively, in HER2+ metastatic breast cancer.
Patient Scenario: HER2+ Metastatic Breast Cancer
Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, consider how they would approach the treatment of a patient with HER2+ metastatic breast cancer.
KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC
Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer.
Selecting Novel Adjuvant Therapy For Patients With Breast Cancer
Following their discussion on the OlympiA and monarchE trials in breast cancer, experts consider when they would use olaparib or abemaciclib in the adjuvant setting.
Adjuvant Abemaciclib in Early Breast Cancer: The monarchE Trial
Shared insight on the monarchE trial, which studied adjuvant abemaciclib in patients with HR+, HER2- high-risk early breast cancer.
Adjuvant Olaparib in BRCA-Mutated Breast Cancer: The OlympiA Trial
Highlights from the OlympiA trial, which evaluated the use of olaparib in the adjuvant setting in patients with high-risk BRCA-mutated breast cancer.
Breast Cancer: The Evolving Neoadjuvant and Adjuvant Treatment Landscape
Joyce O'Shaughnessy, MD, provides a brief overview of novel neoadjuvant and adjuvant treatment approaches being investigated in the setting of breast cancer.
Impact of Molecular Testing on Treatment Options in Breast Cancer
Shared insight on specific treatment options in breast cancer made available when patients are found to have actionable targets via molecular testing.
Molecular Testing Platforms in Breast Cancer
Expert perspectives on platforms for molecular testing in breast cancer, as well as the actionable targets that treating physicians should be looking for.
ESMO 2021: Updates in Triple Negative Breast Cancer
Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.
Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial
Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.
Multidisciplinary Care in ILD Management: Role of a Pulmonologist
Shared insight on the benefit of multidisciplinary care and the pulmonologist’s role in identifying and managing interstitial lung disease.
Role of Bronchoscopy in Identifying and Managing ILD
Charles A. Powell, MD, MBA, leads a discussion on bronchoscopy’s role in identifying interstitial lung disease.
Optimizing the Management of ILD: Steroids, Therapy Cessation, and Dose Modification
A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.
Managing ILD: Taking Therapeutic Class Into Account
Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.
Approaching the Management of Interstitial Lung Disease
Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.
Dr. O’Shaughnessy on the Utility of Tucatinib in the HER2+ Breast Cancer Brain Metastases
Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.
Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast Cancer
Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.
Frontline Dostarlimab Shows Superior PFS vs Pembrolizumab in NSCLC
Dr. Hurvitz on Trastuzumab Deruxtecan in Unresectable/Metastatic HER2+ Breast Cancer
Eribulin Demonstrates Comparable Efficacy to Traditional Chemotherapy Options in HER2-low and HER2-0 Metastatic Breast Cancer
Yoga, Exercise Associated With Better Survival in Nonmetastatic Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.